CORE Core Specialty Insurance Holdings, Inc. S-1 IPO prospectus section summaries

An AI model summarized each section of the prospectus on its own; the summary was written from these. They are longer and less edited than the summary, and the filing on SEC is the authority.

Cover page

Preliminary IPO prospectus

Core Specialty Insurance Holdings, Inc. filed a preliminary Form S-1 on November 16, 2026, for an initial public offering of common stock. The offering is entirely secondary: selling stockholders will sell the shares, and the company will receive no proceeds. The offering price, number of shares, underwriting discounts, and other key offering amounts are blank in the preliminary prospectus. Selling stockholders granted underwriters a 30-day option to purchase additional shares; the number of shares subject to the option is unspecified.

The company intends to apply to list its common stock on the NYSE under the ticker CORE. No public market previously existed. Core Specialty is identified as a specialty insurer; this cover section provides no operating or financial results or substantive business-risk details.

About this prospectus

About this prospectus

Core Specialty cautions that industry and market data, forecasts, and projections are based on third-party sources, internal research, and management estimates. The information has not been independently verified and is subject to uncertainty; investors should not place undue reliance on it.

Insurance measures and terminology

  • Combined ratio is the sum of the loss and loss adjustment expense (LAE) ratio and the underwriting expense ratio.
  • Loss and LAE ratio is net losses and LAE divided by net premiums earned (NPE).
  • Underwriting expense ratio is underwriting, acquisition, and insurance expenses, less fees and commission income, divided by NPE.
  • Expense ratio is net acquisition costs and operating expenses divided by NPE.
  • Underwriting profit (loss) excludes investment income, interest expense, investment gains and losses, amortization, certain parent-company and transaction expenses, and other income and expenses.
  • GPW and NPW mean gross and net premiums written; ALAE and ULAE mean allocated and unallocated loss adjustment expenses; IBNR means incurred-but-not-reported reserves.

Company structure and transactions

  • The Lancer Merger, a stock-and-cash transaction combining Core Specialty and Lancer Financial Group, closed on December 31, 2021. Core Specialty assumed Lancer’s three junior subordinated debentures in the merger.
  • Under the Enstar loss portfolio transfer (LPT), Enstar reinsured all net loss and LAE liabilities of the StarStone Insurance Subsidiaries related to premiums earned through October 31, 2020.
  • The Credit Facility is an unsecured revolving facility dated October 13, 2021.
  • Core Specialty’s Series A cumulative convertible preferred stock automatically converts into common stock at a fixed 1:1 ratio immediately before the offering.
  • The existing Stockholders Agreement is to terminate immediately before the offering is consummated. The Company intends to list its common stock on the NYSE.

Prospectus summary

Core Specialty overview and strategy

Core Specialty is a specialty property and casualty insurer founded in 2020. It describes itself as the fourth-largest U.S. pure-play specialty insurer by gross premiums written (GPW). Its strategy combines diversified specialty underwriting with decentralized divisions accountable for profitability, and reallocates capital toward lines meeting return targets. Management says the company’s formation and profitable growth benefited from market dislocation during COVID-19.

The company operates 17 divisions across Property & Short-tail, Specialty Casualty, and Bond, Credit & Guarantee, covering lines such as agriculture, property catastrophe, marine and energy, commercial auto, workers’ compensation, healthcare liability, mortgage reinsurance, and surety. Divisions have local authority over underwriting, distribution, claims, and talent. Incentives are focused primarily on underwriting profitability, with growth rewarded only when accident-year combined-ratio targets are met; underwriter incentive compensation is paid over three years.

Growth has come from organic expansion, new division launches, and acquisitions, including StarStone US in 2020 and the 2021 Lancer merger. Core Specialty has added 13 divisions since formation. It intends to pursue selective launches and bolt-on acquisitions, avoid legacy liabilities or obtain adverse-development protection, and pull back from business that misses return targets. If attractive opportunities are insufficient, it may return capital. A cloud-based underwriting and claims platform supports expansion and data-driven decisions. Distribution includes agents, brokers, program administrators, MGAs, and financial institutions; excess and surplus (E&S) business represented 30% of TTM September 2026 GPW.

Financial performance

Measure 9M 2026 9M 2025
Gross premiums written $4.0154B $3.7752B
Net premiums written $2.2328B $2.6071B
Net premiums earned $2.0366B $2.3256B
Net investment income $149.6M $129.4M
Net realized and unrealized investment results $(105.3)M $39.0M
Total revenue $2.1575B $2.5534B
Net incurred losses and loss-adjustment expenses $1.3111B $1.6326B
Net income $84.9M $135.2M
Net income attributable to common stockholders $68.8M $111.8M
Core net operating earnings (non-GAAP) $172.8M $104.9M

GPW increased 6.4%, while net premiums written declined 14.4%, net premiums earned declined 12.4%, and total revenue declined 15.5%. Higher investment income was more than offset by the swing from investment gains to losses, contributing to lower reported revenue. Lower incurred losses improved underwriting results.

Underwriting and return measure 9M 2026 9M 2025
Loss and LAE ratio 64.4% 70.2%
Underwriting expense ratio 28.6% 28.0%
Combined ratio 93.0% 98.2%
Return on average adjusted equity 6.9% 11.8%
Core net operating return on average adjusted equity (non-GAAP) 14.0% 9.2%

Despite the decline in GAAP net income, core net operating earnings rose 64.7%. 9M 2026 included a $7.7M negative provision for legal settlement; 9M 2025 had no such provision.

Annual measure FY 2025 FY 2024 FY 2023
Revenue $3.3708B $3.2172B —
Net income $118.9M $167.0M —
Core net operating earnings (non-GAAP) $166.3M $155.5M —
Combined ratio 97.4% 96.1% 98.3%

FY 2025 included a $25.0M legal-settlement provision and a $72.0M loss on abandonment of software assets. GPW grew from $457.3M in 2020 to $4.5665B in 2025, a five-year CAGR of 58.4%; annual growth slowed from 299.5% in 2021 to 1.8% in 2025. TTM September 2026 GPW was $4.8B: $1.6B from new divisions, $1.3B from divisions present at formation, and $1.9B from acquired divisions. Divisions retained since formation grew GPW from $457M in 2020 to $1.3B TTM September 2026, a 19.0% CAGR.

Capitalization and risk management

At September 30, 2026, total assets were $9.7806B and total liabilities were $8.1705B. The reported combined line for mezzanine equity and stockholders’ equity was $1.6101B, including $165.0M of mezzanine equity; adjusted stockholders’ equity, a non-GAAP measure, was $1.7317B. The company also reported stockholders’ equity of $1.4B. Goodwill and definite-lived intangible assets were reported together at $146.8M, without separate amounts. Total investments were $4.3668B; cash and cash equivalents were $262.2M, plus $25.6M restricted cash. Insurance reserves were $4.8053B, reinsurance recoverables $2.1532B, and long-term debt $397.0M. Debt, subordinated debentures, and hybrid securities were 26.4% of total adjusted capitalization, down from 29.1% at FY 2023; debt excluding subordinated debentures and hybrids was 17.0%, versus 18.3%.

Core Specialty identifies catastrophe and severe-weather losses, climate change, pandemics, pricing and reserve adequacy, social inflation and litigation, competition, and soft-market conditions as key risks. Its property reinsurance program retained $28.3M per property event at September 30, 2026, excluding reinstatement premiums, and provided up to $566M of coverage—stated as equivalent to its estimated peak zone in a 250-year event. Reinsurance recoverables were from reinsurers rated AM Best “A-” or better or were collateralized.

An Enstar loss portfolio transfer and adverse development cover protect net losses and LAE on legacy StarStone business earned through October 31, 2020. The cover originally provided $130.0M above $464.4M of assumed reserves; favorable development raised the remaining limit to $143.8M at September 30, 2026. The company attributes its “clean balance sheet” to this protection and reserves written or acquired since 2020. It reports an AM Best financial strength rating of “A” (SLAICO: “A-”) and a “Strongest” balance-sheet strength assessment, with BCAR 25 at 99.6.

Other identified risks include broker concentration, reinsurer credit and payment risk, economic conditions, regulation, IT and data security, personnel retention, and expansion or acquisition execution. The company also disclosed a material weakness in internal control and cautioned that failure to remediate it or maintain effective controls could affect results, financial condition, and share price.

Offering and dividends

The offering is a sale by existing stockholders, who receive all net proceeds; Core Specialty receives none. Selling stockholders granted underwriters a 30-day option to purchase additional shares. The company intends to pay quarterly dividends, subject to board discretion and statutory limits on insurance-subsidiary dividends.

Risk factors

Risk factors

Insurance, catastrophe and market risks

CORE’s principal risks arise from its catastrophe-exposed property and casualty insurance business, dependence on accurate underwriting and reinsurance, and a softening insurance market. Its exposures include hurricanes, storms and floods, tornadoes and hail, earthquakes, wildfires and pandemics. Severe or repeated catastrophes could produce property and non-property claims that exceed reinsurance protection, creating significant volatility in earnings and financial condition. Changing climate and weather patterns may make losses harder to model, price and reserve for; increase claims across multiple lines; disrupt operations; and raise the cost of reinsurance or reduce its availability. Rate-approval delays or inaccurate models could leave premiums inadequate. CORE also notes that private reinsurance is generally limited for terrorism involving nuclear, biological, chemical or radiological weapons. The Terrorism Risk Insurance Program is extended through December 31, 2027, subject to deductibles and other limits.

Profitability depends on reliable data and accurate estimates of loss frequency and severity. Underpricing can erode margins, while overpricing can reduce competitiveness and sales. Actual claims may exceed reserves as claim severity, repair and medical costs, inflation, litigation, social inflation and legal standards evolve. Reserve deficiencies would reduce income and equity when recognized and could impair liquidity, financial strength ratings, future earnings or common dividends. CORE’s underwriting, pricing, reserving, claims and catastrophe decisions rely partly on models and assumptions; inaccurate data, limitations or errors—including in AI-generated analyses—could distort risk estimates. Renewal assumptions also may prove wrong: weaker renewals, or decisions not to renew unattractive business, could reduce future premiums and results.

The P&C market is cyclical and currently soft. Specialty-lines pricing fell faster than expected in 2025; WTW’s survey reported 2026 rates, including renewals around January 1, at levels not seen since 2020. Competition and less restrictive underwriting can pressure premiums and retention. Customers who moved to excess-and-surplus coverage may return to the admitted market, and CORE may not retain them. Competition may also intensify through consolidation, new entrants, competitors’ greater resources or more effective use of AI. CORE’s three largest wholesale brokers together accounted for 39% of gross premiums written in the nine months ended September 30, 2026; losing a key broker, broker consolidation or narrower insurer panels could reduce access to business or negotiating leverage.

Reinsurance does not release CORE from its obligations to policyholders. Recoveries may be delayed, disputed or unpaid because of reinsurer insolvency, liquidity or operational problems, restrictions, fraud or coverage disputes; recoverables totaled $2.2 billion at September 30, 2026. Failure to collect could increase net losses. Adequate reinsurance may also be unavailable or costly, particularly if the market hardens. Crop-insurance results are exposed to weather, pests, disease and commodity prices, including declines in major crop prices. CORE’s limited operating history—it was founded in May 2020—and its strategy of growth through acquisitions or expansion into lines and geographies add uncertainty around integration, personnel, regulatory matters, claims, valuation and assumed liabilities.

Capital, regulation and financial risks

As of the prospectus date, all Insurance Subsidiaries were rated A (Excellent) by AM Best except SLAICO, rated A- (Excellent). A downgrade or withdrawal could weaken demand, restrict business, or raise the cost or reduce the availability of reinsurance. Potential causes include reserve shortfalls, investment losses or limited liquidity, and adverse market or regulatory developments.

At September 30, 2026, CORE had $361.5 million outstanding under its $500 million Credit Facility, which matures October 13, 2027. The facility limits additional debt, liens, investments, dividends and other distributions, asset sales, mergers and certain affiliate transactions; it requires total indebtedness to total capital of no more than 35% and compliance with a minimum-net-worth covenant. Default could accelerate amounts due, while failure to refinance or obtain capital on acceptable terms could impair operations and financial condition. Market volatility may also constrain access to equity or debt capital. CORE may have to sell investments to meet claims; sales in adverse markets could be unavailable or occur at unfavorable prices, generating realized losses.

As a holding company, CORE relies substantially on subsidiary distributions for parent debt service and common dividends. State rules and regulators can restrict distributions; subsidiaries had capacity to pay up to $166.6 million in 2026 without prior regulatory approval, but this does not assure the full amount can be distributed. Insurance subsidiaries also face extensive state requirements concerning capital, investments, underwriting, dividends, licensing and solvency. Noncompliance or failure to meet NAIC risk-based capital requirements could lead to penalties, supervision, rehabilitation or liquidation, and threaten licenses or ratings. E&S business has greater rate and form flexibility, but regulatory outcomes can be less predictable. New laws, including climate-disclosure requirements, and accounting or tax changes could add costs or affect reported results, equity and cash flows.

Recession, unemployment and weaker activity could reduce insurance demand and premiums and increase cancellations, defaults or fraud. Inflation may raise claims and operating costs; CORE stated it had not materially affected overall results to date, but prolonged above-average inflation could erode underwriting profit if rates do not keep pace. Interest-rate changes, issuer-credit deterioration, tariffs and economic uncertainty may also affect its fixed-maturity investments, insured exposures, claims and costs. Evolving ESG rules and stakeholder expectations could raise compliance costs, restrict opportunities or cause reputational harm.

Operations, technology and controls

CORE depends on IT, cloud systems and third parties for core claims, policy administration and distribution. Cyberattacks, ransomware, outages, data breaches or vendor failures could disrupt operations, expose sensitive information and cause losses, litigation, penalties and reputational damage; insurance may not cover all costs. CORE handles personal and protected health information, including in Medical Stop-Loss, and faces obligations under HIPAA, GLBA and state privacy laws. Third-party data safeguards cannot be assured. Duck Creek supplies its underwriting and claims platform, while Workday supports significant finance and human-capital processes; replacing vendors could be difficult and costly.

Management identified material weaknesses while preparing the 2024 financial statements. All but one have been remediated; the remaining weakness concerns processes, systems, personnel and controls over third-party data. Remediation is underway, including stronger validation of data from managing general agents and third-party administrators, but neither CORE nor its auditor has tested effectiveness. Management’s Section 404(a) assessment begins with the FY2026 annual report; auditor attestation under Section 404(b) is exempt until FY2027. Control failures could impair reporting, prompt litigation or regulatory scrutiny, undermine confidence or threaten NYSE listing. Additional operational risks include executive and specialized-talent departures, fraud, control failures and ineffective enterprise risk management.

Public-company and stock risks

CORE expects public-company reporting, governance and compliance obligations to increase costs and divert management attention. No public market existed before the offering, and an active NYSE market may not develop or persist; the IPO price may not reflect later trading prices, and investors may be unable to sell when or at the price they want. Lock-up expirations or waivers, registered incentive-plan shares, registration rights and future stock issuance for acquisitions or investments could increase supply and pressure the share price. Price volatility may reflect market conditions, results, analyst coverage, legal or regulatory developments, management changes, debt or securities issuance and large shareholder sales, and could lead to securities litigation.

Governance provisions—including preferred-stock issuance authority, limits on special meetings, no cumulative voting, Board control over vacancies and a 75% voting threshold for specified charter amendments—could impede a takeover offering a shareholder premium. Exclusive-forum provisions may limit litigation venues; enforceability of the federal securities forum provision is uncertain. **

Forward looking statements

Forward-Looking Statements and Key Risks

The prospectus’s forward-looking statements address expected financial condition and results, liquidity, growth strategy, capital expenditures, distributions, and the company’s belief that it can meet known obligations. They reflect current information and assumptions, are not guarantees, are not exhaustive, and actual outcomes may differ materially. The company generally undertakes no obligation to update them after the prospectus date except as required by law.

Key insurance risks include catastrophe, severe-weather and climate-related losses; underwriting and pricing uncertainty; claims and coverage disputes, including social inflation; a soft, cyclical insurance market; reliance on a few brokers; inadequate loss reserves; competition; and ineffective risk-management methods. The company also faces credit and recovery risks involving reinsurers and program managers, including delayed or failed reinsurance recoveries. Adverse economic conditions could affect policy sales, claims frequency and premium defaults; investment losses could arise if assets must be sold to meet obligations.

Other risks include executing acquisitions and expansion plans, regulatory changes, retaining key personnel, technology and cybersecurity threats, higher costs as a public company, and failure to maintain effective Sarbanes-Oxley controls. No financial results or quantitative metrics are provided in this section.

Use of proceeds

Use of Proceeds

This is a secondary offering. CORE will receive no proceeds from shares sold by the selling stockholders, including any shares sold under the underwriters’ option to purchase additional shares; the selling stockholders will receive all net proceeds. CORE will pay offering expenses other than underwriting discounts and commissions. The offering is intended to establish a public market for CORE’s common stock, facilitate future access to public equity markets, and increase the company’s visibility in the marketplace.

Dividend policy

Dividend policy

CORE expects to pay quarterly cash dividends. The per-share amount is blank in the provided excerpt. Future dividends, including their amount, are at the Board’s discretion and depend on the Insurance Subsidiaries’ ability to distribute funds.

CORE is a holding company with no significant operations of its own and relies principally on subsidiary dividends and other payments to meet its obligations, including any common-stock dividends. Insurance-law limits and minimum regulatory capital requirements may restrict subsidiary distributions. In deciding whether to pay dividends, the Board may also consider CORE’s financial condition, liquidity and capital needs, legal or contractual restrictions, and possible effects on financial-strength or other ratings.

Capitalization

Capitalization as of September 30, 2026

Cash and cash equivalents were $262.2M, compared with total debt of $397.3M, leaving debt $135.1M above cash. The revolving credit facility accounted for most of the debt.

Debt Amount
Revolving credit facility $361.5M
JSD I $15.5M
JSD II $4.1M
JSD III $6.2M
Surplus note $10.0M
Total debt $397.3M
Capitalization Actual As adjusted
Total equity $1,610.1M $1,610.1M
Total capitalization (equity plus debt) $2,007.4M $2,007.4M
Adjusted capitalization, including $121.6M of unrealized losses, net of tax $2,129.0M $2,129.0M
Debt, subordinated debentures and hybrid securities / adjusted capitalization 26.4% 18.7%
Debt excluding subordinated debentures and hybrid securities / adjusted capitalization 17.0% 17.0%

The as-adjusted presentation reflects the automatic conversion of 1,684,129 Series A cumulative convertible preferred shares into common shares immediately before the offering. The conversion changed the composition of equity, but not total equity or capitalization.

Equity and shares Actual As adjusted
Preferred stock $165.0M $0
Common stock $0.1M $165.1M
Common shares outstanding 10,120,129 11,804,258
Treasury stock $(4.2)M $(4.2)M
Additional paid-in capital $1,026.4M $1,026.4M
Retained earnings $422.8M $422.8M
Stated book value per common share $142.79 $136.40
Adjusted book value per common share, incorporating trading-portfolio unrealized losses, net of tax $154.80 $146.70

Although total equity was unchanged, the increase in common shares outstanding following conversion reduced stated and adjusted book value per common share.

Management's discussion and analysis

Core Specialty — MD&A summary

Q3 and nine-month 2026 results

Measure Q3 2026 Q3 2025 9M 2026 9M 2025
Gross premiums written $1,023.3M $996.7M $4,015.4M $3,775.2M
Net premiums earned $682.1M $773.7M $2,036.6M $2,325.6M
Net losses and LAE $438.4M $532.6M — —
Underwriting profit $46.6M $14.7M $143.2M $41.5M
Net investment income $52.4M $44.6M $149.6M $129.4M
Net realized and unrealized investment gains (losses) $(68.5)M $16.5M $(105.3)M $39.0M
Income (loss) before tax $(1.7)M $66.2M $108.3M $172.6M
Net income (loss) $(1.4)M $51.7M $84.9M $135.2M
Core net operating earnings* $60.6M $38.2M $172.8M $104.9M
Combined ratio 93.2% 98.1% 93.0% 98.2%

Underwriting strengthened, but the investment-result swing more than offset the improvement in GAAP earnings. In Q3, underwriting profit rose $31.9M and net investment income rose $7.8M, while net realized and unrealized investment results moved from gains to losses. For 9M, underwriting profit increased $101.7M and net investment income increased $20.2M, but investment losses and a $38.2M increase in parent-company and other expenses contributed to lower pretax income. Core results exclude investment gains and losses and certain other items; management presents them as a supplement to GAAP results.

Q3 net premiums earned declined despite growth in gross premiums written, reflecting higher ceded premiums and the timing of earned premiums. For 9M, ceded premiums rose 53% to $1,782.6M from $1,168.1M, increasing ceded premiums to 44% of gross premiums from 31%. Net premiums written consequently fell 14% to $2,232.8M from $2,607.1M. Net investment income benefited from higher average cash and investments: up 13% in Q3 and 15% for 9M; yields were 4.56% and 4.45%, respectively, versus 4.36% and 4.43%.

Underwriting by business

Business Q3 GPW 2026 / 2025 Q3 NPE 2026 / 2025 Q3 underwriting profit 2026 / 2025 9M GPW 2026 / 2025 9M NPE 2026 / 2025 9M underwriting profit 2026 / 2025
Property & Short-tail $207.0M / $194.9M $200.7M / $285.3M $22.5M / $24.1M $1,564.9M / $1,545.8M $595.9M / $877.8M $75.6M / $52.0M
Specialty Casualty $679.8M / $702.4M $378.1M / $387.0M $18.9M / $1.3M $2,061.3M / $1,907.9M $1,131.1M / $1,144.0M $46.8M / $25.8M
Bond, Credit & Guarantee $136.5M / $99.4M $103.3M / $101.4M $5.2M / $(10.7)M $389.2M / $321.5M $309.6M / $303.8M $20.8M / $(36.3)M

Q3 growth in Bond, Credit & Guarantee reflected Financial Services and Surety; its improved result also benefited from lower current-year losses and acquisition costs. Property & Short-tail growth in Agriculture was offset by competitive Property conditions and renewal rates down about 6%; increased Agriculture reinsurance cessions also weighed on net premiums. Specialty Casualty GPW declined as the company de-prioritized fronted business, partly offset by Excess Casualty and Medical Stop-Loss growth; renewal rates rose about 7%.

For 9M, Property & Short-tail renewal rates fell about 17% amid competitive pricing, while Specialty Casualty rates increased about 8%. Specialty Casualty growth included a new fully fronted assumed-reinsurance contract and growth in Excess Casualty and Workers’ Compensation, partly offset by non-renewed programs. Overall renewal rates were down about 1%. The 9M combined ratio improvement reflected a lower loss and LAE ratio (64.4% versus 70.2%), partly offset by a higher underwriting expense ratio (28.6% versus 28.0%). Favorable prior-year reserve development was $32.9M, versus $9.0M unfavorable in 9M 2025; Specialty Casualty nevertheless had $26.6M adverse development.

Cash flow, capital and debt

Cash flow 9M 2026 9M 2025
Operating cash flow $440.4M $611.5M
Investing cash flow $(446.3)M $(449.5)M
Financing cash flow $11.9M $(10.9)M
Net change in cash $6.0M $151.1M

Investing outflows mainly reflected purchases of trading securities exceeding sales and maturities, plus fixed-asset purchases. Financing included $25.0M of Credit Facility borrowings and $5.8M of common-stock repurchases; preferred dividends were $4.7M in both periods.

Capital measure Sep. 30, 2026 Dec. 31, 2025
GAAP common stockholders’ equity $1,445.1M $1,362.5M
Adjusted stockholders’ equity* $1,731.7M $1,560.0M
Adjusted book value per share* $146.70 $132.45
Debt, subordinated debentures and hybrid securities $562.3M $537.3M
Adjusted capitalization* $2,129.0M $1,932.3M

Adjusted equity adds $165.0M of Series A cumulative convertible preferred stock and adjusts for after-tax unrealized fixed-maturity trading losses. Debt excluding subordinated debentures and hybrids was $361.5M, compared with $336.5M; other components included $25.8M of junior subordinated debentures and a $10.0M surplus note. Total debt and hybrids were 26.4% of adjusted capitalization, within management’s 40% target (25% excluding hybrids); the Credit Facility covenant limits debt to 35% of total capitalization. The $500M facility matures October 2027; borrowings were $361.5M at 5.13%, with $138.5M unused capacity. Management estimated approximately $671M of excess capital, including financing capacity, assuming maximum debt and hybrid use within its target. Subsidiaries paid $22.2M in dividends to the parent during 9M; their capacity for dividends without prior regulatory approval was $166.6M at year-end 2025.

Investment, reserve and other risks

Trading fixed maturities had $4.2879B fair value and $4.4418B book value at September 30, 2026; fair-value changes flow through earnings. A 100-basis-point rate increase was estimated to reduce fair value by $102.9M (2.4%); a 200-basis-point increase by $205.8M (4.8%). More than 99% of the portfolio was investment grade, with an average A+ rating, though BBB exposure rose to 27% from 16% at year-end 2025. Corporate bonds were 74% and CLOs 21% of fair value. Reinsurer credit exposure remains material because Core Specialty remains liable to policyholders if reinsurers do not pay; at September 2026, 83% of recoverables were with reinsurers rated A- or better and 17% were collateralized.

Loss and LAE reserves were $4.7B at September 30, 2026. At year-end 2025, contractual obligations totaled $4.6465B, including $4.2388B of gross loss and LAE reserves; $1.7919B was due within one year, although reserve payment timing is uncertain. P&C reserve recoverables were $2.0557B at September 30, 2026, net of a $4.7M credit allowance. Reserve estimates are sensitive to inflation, medical costs, litigation, legal changes, catastrophe experience and claim trends. A 1% change in future cost trends was estimated to affect FY2025 net income by $33.4M for Other Liability–Occurrence, $5.9M for Commercial Auto and $5.4M for Other Lines.

Management describes the P&C market as soft, with intense competition and less restrictive underwriting. Reinsurance may become less available or more expensive, and reserve deficiencies, reinsurer distress, investment losses or ratings downgrades could require additional capital. The holding company depends on regulated subsidiary dividends for corporate costs, debt service and shareholder payments.

FY2025 context

FY2025 GPW was $4,566.5M, versus $4,487.7M in FY2024; combined ratios were 97.4% and 96.1%. Net income fell to $118.9M from $167.0M, while core net operating earnings increased to $166.3M from $155.5M. FY2025 net income included a $72.0M software-asset abandonment loss and a $25.0M estimated legal-settlement provision; net realized and unrealized investment gains were $39.5M. The 2025 underwriting expense ratio rose to 28.1% from 26.0%, partly offset by a lower loss and LAE ratio. Core earnings and adjusted equity measures are non-GAAP.

Adoption of ASU 2025-05 on credit losses had no material impact; the company was evaluating ASU 2025-06 on internal-use software costs.

Business

Business overview and growth

Core Specialty was formed in 2020 to build a diversified U.S. specialty insurer. Its formation included $610M of new investor equity and approximately $60M of additional management and other investor commitments; together with Enstar’s rolled-over ownership, capitalization exceeded $900M. Legacy reserves are protected by an Enstar loss portfolio transfer and adverse development cover, pre-existing reinsurance, and a separate arrangement under which former Lancer shareholders retained the financial impact of 2020-and-prior reserve development within a symmetrical range of up to $30M.

The company expanded from four divisions to 17 through organic growth and acquisitions. Gross premiums written (GPW) grew at a 58.4% CAGR from FY2020 through FY2025. Of $4.8B GPW for the 12 months ended September 30, 2026, $1.6B came from start-up divisions, $1.3B from divisions existing at inception, and $1.9B from acquired divisions. Inception divisions retained by the company grew from $457M GPW in FY2020 to $1.1B in FY2025, a 20.0% CAGR.

The 17 divisions cover Property & Short-tail, Specialty Casualty, and Bond, Credit & Guarantee. Their products include catastrophe-exposed property, commercial auto and trucking, professional and healthcare liability, medical stop-loss, crop and mortgage reinsurance, and surety. The portfolio combines admitted and excess-and-surplus business, primary and excess insurance, and assumed reinsurance.

Acquisitions broadened capabilities and distribution, including Lancer (2021), Hallmark E&S renewal rights and employees (2022), Conifer Security & Alarm renewal rights (2023), American National medical stop-loss operations and a Specialty Markets Group transfer (2023–24), American Surety (2024), and Argo professional-lines renewal rights and London Aviation Underwriters (2025). Several transactions involved renewal rights and unearned premium reserves rather than legacy loss reserves; management describes its approach as selective to limit legacy-risk exposure.

Insurance operating results

Nine months ended September 30 ($M, except ratios)

Measure 9M 2026 9M 2025
Gross premiums written $4,015.4 $3,775.2
Ceded reinsurance $1,782.6 $1,168.1
Net premiums written $2,232.8 $2,607.1
Net premiums earned $2,036.6 $2,325.6
Net commission income $76.6 $59.5
Loss and LAE $1,311.1 $1,632.6
Underwriting expenses $658.9 $711.0
Underwriting profit $143.2 $41.5
Loss and LAE ratio 64.4% 70.2%
Underwriting expense ratio 28.6% 28.0%
Combined ratio 93.0% 98.2%

GPW increased 6.4%, but higher ceded reinsurance reduced net premiums written 14.4% and net premiums earned 12.4%. Despite lower earned premiums, underwriting profit improved substantially, primarily alongside lower losses and LAE. Management prioritizes accident-year underwriting profitability over premium growth; division incentives target underwriting profitability rather than premium volume or underwriting income.

Full-year GAAP insurance results ($M, except ratios)

Measure FY2025 FY2024 FY2023
Gross premiums written $4,566.5 $4,487.7 $3,477.2
Ceded reinsurance $1,477.6 $1,333.8 $954.1
Net premiums written $3,088.9 $3,153.9 $2,523.1
Net premiums earned $3,072.7 $2,968.1 $2,296.6
Net commission income $82.0 $76.5 $44.1
Loss and LAE $2,128.1 $2,080.3 $1,684.9
Underwriting expenses $946.6 $849.2 $617.0
Underwriting profit $80.0 $115.1 $38.8
GAAP loss ratio 69.3% 70.1% 73.4%
GAAP expense ratio 28.1% 26.0% 24.9%
GAAP combined ratio 97.4% 96.1% 98.3%
Statutory combined ratio 99.6% 100.9% 98.8%

The FY2023–FY2025 average statutory combined ratio was 99.8%, compared with 96.3% for commercial lines and 98.0% for the P&C industry. Management nevertheless says it has outperformed over the five years since formation. Combined ratios exclude investment income and taxes; a ratio below 100% indicates underwriting profit.

Underwriting, distribution and risk management

Divisions have autonomy over underwriting, pricing, distribution, claims, reinsurance design and talent, while corporate functions oversee capital allocation, investments, reinsurance purchasing, risk management, actuarial matters and compliance. Monthly and quarterly reviews monitor premiums, combined ratios, claims, large losses, pricing and competitors. Claims are handled by division teams, with corporate oversight of third-party administrators through system access, high-exposure claim reviews and file audits. A centralized, SaaS-based underwriting and claims platform supports analysis and risk selection; the company says underwriters can respond to many broker submissions within 24 hours. Technology, data-security risks, claims outcomes and integration of acquired businesses remain considerations.

Distribution is primarily through independent agents and brokers. At December 31, 2025, the company had 51 active programs, including 14 in Medical Stop-Loss. FY2025 GPW was 68% direct and 32% assumed reinsurance; distribution was 39% wholesale brokers, 18% retail agents/brokers, 39% program administrators and 4% lenders/financial institutions. Amwins accounted for 29%, 21% and 19% of GPW in 2023, 2024 and 2025, respectively; Marsh & McLennan represented 17%, 13% and 12%. For 9M 2026, Amwins, Marsh and Stratus represented 11%, 14% and 14%, respectively. Dependence on major distribution partners and program administrators is a concentration risk.

The company uses reinsurance to limit catastrophe losses and support policy limits, while remaining obligated to policyholders if a reinsurer fails to pay. Its 2025 property catastrophe program included 35% quota-share coverage of applicable vertical losses; $310M of traditional excess-of-loss cover above a $150M per-event primary retention; and Yosemite Re catastrophe-bond cover of up to 86% of $110M above $280M. The combined tower was designed for an approximately $570M 1-in-250-year property loss. Beginning in 2025, corporate catastrophe excess-of-loss protection also covered combined division exposure, net of inuring reinsurance. The company targets protection against modeled 1-in-250-year events, with net exposure described as approximately 5% of adjusted stockholders’ equity; a separate description says losses for such an event are expected below 5%.

For crop business, multi-peril coverage provides up to $200M excess of a 100% loss-and-LAE ratio; a repeat of the 2012 drought is estimated to produce a $50M pretax loss. For the 2026 reinsurance year, approximately 50% of multi-peril and private-product crop business was ceded under quota-share arrangements. Medical stop-loss excess-loss reinsurance covers 100% above $1M and $2M layers. The 2020 Enstar legacy-loss cover has a $130M limit above $464.4M of assumed reserves. As of September 30, 2026, StarStone stop-loss agreements had $794.2M of aggregate remaining coverage for underwriting years 2016–2020, reduced by approximately $16.9M of ceded losses.

Reinsurance recoverables at December 31, 2025 included $124.3M on paid losses and LAE and $1.7B on unpaid losses and LAE. Gross recoverables were $1.9129B, less a $4.7M expected-credit-loss allowance, for $1.9082B net. The top 10 reinsurers accounted for $1.1305B (59.1%); National Indemnity was the largest at $337.2M (17.6%). Reinsurers are generally rated A- or better or collateralized, but credit deterioration could produce losses above the allowance.

Loss reserves rely on case reviews, actuarial projections and management judgment, including estimates of IBNR and development on reported claims. They are not discounted; changes in claims frequency, severity, inflation or new information can affect current-period earnings. Net current-accident-year catastrophe losses were $26.5M in 9M 2026 versus $48.3M in 9M 2025, and $56.7M in FY2025, $134.9M in FY2024 and $71.7M in FY2023. Risk selection, limits on coastal and fault-line exposure, and reinsurance mitigate catastrophe exposure.

Investments and other exposures

At September 30, 2026, the investment portfolio was described as $4.7B, almost entirely cash, cash equivalents and investment-grade fixed income, managed by Goldman Sachs Asset Management under board-approved guidelines.

Investment measure September 30, 2026
Fixed maturities, amortized cost, net $4.4418B
Fixed maturities, fair value $4.2879B
Investment-grade holdings, amortized cost, net $4.4353B
Investment-grade holdings, fair value $4.2824B
Investment-grade share / average credit rating Over 99% / A+
Weighted-average effective duration 2.4 years
Average yield, 9M 2026 4.45%

Average yield was 4.44% in FY2025, 4.42% in FY2024 and 3.94% in FY2023. The strategy emphasizes capital preservation, liquidity, high-quality securities and matching asset duration to insurance liabilities; there was no public-equity exposure and minimal alternative-investment exposure at December 31, 2025.

Mortgage reinsurance, which began in 2023, is concentrated in pools associated with Fannie Mae, Freddie Mac and private mortgage insurer Enact. Crop insurance has high entry barriers, including federal approval requirements for primary insurers. In 2025, California, New York, Texas and Florida represented 19.6%, 13.0%, 10.2% and 9.3% of statutory direct premiums written, respectively. All six insurance subsidiaries had stable AM Best ratings at December 31, 2025: five were rated A and Standard Life and Accident Insurance Company was rated A-. Management considers an A- or higher rating important to competing in most lines. The company had approximately 1,139 employees at September 30, 2026; it reported no collective bargaining agreements or known organizing efforts.

Regulation

Regulation

Insurance operations and holding-company liquidity

CORE is a holding company without its own operating business. Its ability to pay shareholder dividends and meet debt obligations therefore depends largely on distributions from its insurance subsidiaries. State limits protect insurers’ statutory capital and surplus, and regulators may restrict payments even when they fall within formula-based limits. As of December 31, 2025, the six subsidiaries had capacity to pay up to $166.6 million in dividends during 2026 without prior regulatory approval; this is not a guarantee that the amount will be paid.

CORE’s six insurance subsidiaries—SNIC, SSIC, LIC, LICNJ, SLAICO and American Surety—are domiciled in Delaware, Illinois, New Jersey, Texas and Indiana, and their licenses were reported in good standing. SNIC, LIC and American Surety operate on an admitted basis in all 50 states and D.C.; LIC is also admitted in Puerto Rico. LICNJ operates in six states and D.C., while SLAICO is admitted in all states except Maine, New Hampshire, New Jersey and New York, plus D.C. SSIC operates as a surplus-lines insurer and is eligible across all 50 states, D.C., Puerto Rico and Guam. In most surplus-lines business, SSIC can change rates, forms and underwriting guidelines without prior approval, providing more flexibility than admitted business.

Solvency and group oversight

As of December 31, 2025, the insurance subsidiaries’ total adjusted capital exceeded levels that would trigger regulatory corrective action. Risk-based capital (RBC) requirements measure capital against insurer size and risks such as assets, credit, underwriting and interest rates. Falling below RBC thresholds can lead to escalating state intervention, up to mandatory control by the domiciliary insurance department, and may impair a subsidiary’s ability to maintain approvals to operate. The NAIC’s IRIS ratios serve as screening and monitoring tools rather than pass/fail tests; results outside usual ranges do not necessarily indicate financial weakness.

The domiciliary states have adopted versions of the NAIC’s enterprise-risk and Own Risk and Solvency Assessment (ORSA) requirements. The insurance group must maintain risk-management processes and conduct an ORSA; regulators may request a summary report, generally no more than once a year. Delaware is lead state for the subsidiaries. Delaware’s group examination report, issued June 3, 2024 and covering the year ended December 31, 2022, reported no issues.

Regulatory constraints and transaction risks

State regulators oversee rates and forms, reserves, statutory accounting, capital and surplus, investments, affiliate transactions, market conduct and licensing. Rules may change. Investments that do not meet regulatory requirements may be treated as non-admitted—reducing statutory surplus—or may have to be sold. Some states also restrict insurers’ ability to withdraw from markets or lines of business, potentially requiring regulator-approved plans and limiting strategic exits. Financial and market-conduct examinations generally occur every three to five years, with targeted examinations possible at any time.

A purchase of 10% or more of CORE’s common stock may be considered an indirect change of control of its insurance subsidiaries, requiring prior approval or a disclaimer-of-control filing in relevant states. Regulators may evaluate an acquirer’s financial strength, management, operating plans and competitive effects. These requirements can delay, deter or prevent an acquisition, including one shareholders might otherwise support.

Reinsurance, cybersecurity and broader regulatory developments

Subsidiaries report to regulators under statutory accounting principles, which emphasize solvency rather than GAAP presentation. CORE states that its material reinsurers satisfy applicable credit-for-reinsurance requirements, allowing the subsidiaries full financial-statement credit for ceded reinsurance; maintaining eligibility is important to retaining that statutory benefit.

Cybersecurity, privacy and conduct requirements create continuing compliance and potential penalty or licensing risks. Nearly half of U.S. states have adopted the NAIC Insurance Data Security Model Law, including Delaware, Illinois and Indiana, where four subsidiaries are domiciled. Requirements include information-security programs and breach investigation and notification. The CCPA applies to specified handling of California residents’ personal information. NYDFS cybersecurity rules impose detailed technical, governance and reporting requirements; amendments adopted in November 2023 increased obligations, amid continuing regulatory scrutiny and enforcement. State laws also prohibit unfair sales and claims practices. Insurers additionally face privacy-law and OFAC sanctions compliance exposure; violations have resulted in civil penalties for insurance and reinsurance companies.

Insurance regulation is primarily state-based, though federal involvement has expanded under Dodd-Frank. The NRRA gives an insured’s home state exclusive authority over surplus-lines insurance regulation and taxation, and assigns reinsurance balance-sheet credit regulation to the ceding insurer’s domiciliary state. In August 2023, the NAIC revised its Nonadmitted Insurance Model Act to reflect NRRA-related changes. Dodd-Frank also allows qualifying ceding insurers to rely on their domiciliary state’s reinsurance-credit rules. Federal Insurance Office recommendations could lead to systemically significant insurer designation and Federal Reserve regulation, but FIO’s authority to preempt state insurance law is limited and subject to consultation and notice; modernization recommendations remain largely advisory, and implementation is uncertain.

Management

Leadership and Board

Founder Jeff Consolino serves as Chairman, President and CEO. He has more than 30 years of insurance and financial-services experience, including senior roles at AFG and Validus and founding and leading specialty insurance businesses. CFO Evan Cabat joined in October 2025 after insurance-company accounting leadership at SiriusPoint and 15 years at EY. General Counsel Michael Powell joined in May 2026; previously, he was Deputy General Counsel and Corporate Secretary of Fifth Third Bank. Chief Underwriting Officer Jeffrey Wanamaker has held that role since October 2020, and COO Cathryn Warner has served since December 2020, following Core Specialty’s acquisition of StarStone US.

Following the offering, the Board is expected to have 12 members, including Consolino; ten directors are identified as independent under NYSE standards. Directors bring experience in property-and-casualty and specialty insurance, reinsurance, financial services, investment and M&A. Several also hold roles or board seats at other insurers, investors and financial-services firms, including Amwins, Enstar, Starr and Dellwood. Patrick Gordon joined the Board in May 2025 and Bart van der Vlugt in June 2026.

The Investor Rights Agreement provides for director appointment rights as follows: Dragoneer and SkyKnight may appoint up to four directors; Enstar and the majority of management stockholders may each appoint two; Aquiline and Delaney Group may each appoint one; and a majority of directors then in office appoints two. These rights decline as investors’ holdings fall, subject to specified retained-share or 5%-ownership thresholds, and are ultimately lost at lower ownership levels.

Board Committees and Governance

Five standing committees are expected after the offering:

  • Audit: Dom Addesso (chair), Sally Pope Davis and Don Larson. All three are identified as independent, and Addesso is the audit committee financial expert. The committee oversees financial reporting and disclosures, internal controls and audit, internal audit, regulatory compliance, risk management and related-party transactions.
  • Compensation: Steve DeCarlo, Paul O’Shea and Don Larson (chair). O’Shea and Larson are identified as independent. Responsibilities include executive and director compensation, incentive and equity plans, compensation-related risk, clawbacks, succession, management development and human-capital policies.
  • Nominating and Corporate Governance: Don Larson, Paul O’Shea, Chris Watson and Steve DeCarlo (chair). Larson and O’Shea are identified as independent. The committee oversees Board composition and nominations, committee assignments and charters, governance guidelines, and Board and committee evaluations.
  • Risk Management: Dom Addesso, Sally Pope Davis, Dave Delaney, Bart van der Vlugt and Chris Watson (chair). Its remit includes risk strategy and appetite, insurance-subsidiary regulatory compliance, operational breaches and remediation, catastrophe scenarios, underwriting authorities, and material changes to underwriting systems.
  • Finance: Jeff Consolino, Sally Pope Davis, Patrick Gordon, David Ni, Bart van der Vlugt and Matt Ebbel (chair). It oversees investments and financing, investment managers and policies, asset allocation, financing facilities and debt covenants, rating-agency evaluations, and dividend recommendations.

The company is using the NYSE IPO transition period for committee independence requirements. NYSE rules require the Compensation and Nominating and Corporate Governance Committees to be fully independent within one year of listing; at formation, each is described as having only two members identified as independent. Written committee charters and a revised Code of Conduct covering directors, officers and employees, including the CEO and CFO, are to be adopted or made available after the offering.

This section contains no financial results or operating metrics.

Executive and director compensation

Compensation approach and FY2025 incentive outcomes

FY2025 executive compensation combined salary, annual cash incentives, long-term incentives and retirement benefits. The company says a significant portion is performance-based, with measures including Core Net Operating Earnings Per Share, Accident Year Combined Ratio and Adjusted Book Value Growth Plus Dividends, including relative performance against an 11-company insurance peer group. Annual incentives emphasize company results; long-term incentives emphasize book-value growth and return on equity. RSUs generally vest in three equal annual installments. The company cites payout caps, multiple pre-established goals and multi-year vesting as safeguards against excessive risk-taking. It prohibits hedging and pledging its securities and does not provide excise-tax gross-ups.

The FY2025 Core Net Operating Earnings Per Share target was $15.75, approximately 15% above the 2024 target. Actual performance grew year over year but fell below the level required for a payout; below 90% of target, no award is earned for this component. Messrs. Consolino, Kuzloski and Vens received no FY2025 Annual Bonus Plan payment. The metric is non-GAAP and excludes, among other items, discontinued operations, net realized gains and losses, and certain special items.

The CEO, General Counsel and former CFO’s annual awards were based solely on company performance. Warner’s target was split 50% between Core Net Operating Earnings Per Share and discretionary goals; Wanamaker’s was split 70% for insurance-operations performance and 30% discretionary. FY2025 discretionary bonuses were $113,815 for Warner and $70,200 for Wanamaker; Wanamaker also received $175,570 in performance-based non-equity incentive compensation.

For the 2023 Senior Executive LTIC performance period (October 31, 2022–December 31, 2025), Adjusted Book Value Growth Plus Dividends was 23.8%, ranking seventh among plan peers and yielding 91% of target for that component. Consolino and Kuzloski received $863,709 and $292,185, respectively, in fully vested shares reported as non-equity incentive compensation; Vens was ineligible after termination.

FY2025 named executive officer compensation

Amounts in dollars. Stock-award values are ASC 718 grant-date fair values, not cash paid.

Executive Salary Bonus Stock awards Non-equity incentive compensation Other compensation Total
Consolino $1,160,368 $0 $950,064 $863,709 $28,352 $3,002,493
Cabat $83,077 $225,000 $0 $0 $175 $308,252
Wanamaker $478,260 $70,200 $250,065 $175,570 $26,552 $1,000,647
Warner $451,690 $113,815 $174,966 $0 $29,174 $769,645
Vens $251,240 $0 $0 $0 $1,017,405 $1,268,645
Kuzloski $637,680 $0 $374,969 $292,185 $28,683 $1,333,517

Vens’s other compensation included $908,929 of severance and $92,766 of accrued vacation. Cabat joined October 31, 2025; his compensation included a $225,000 guaranteed bonus and $125,000 cash sign-on bonus.

Employment terms, equity and potential obligations

Consolino’s initial annual salary was $1.000 million, rising to $1.20463 million on March 29, 2026. His agreement provides a cash-bonus target of 150% of salary, capped at 133% of target; a stock-bonus opportunity of up to $1.900 million tied to relative Adjusted Book Value Growth Plus Dividends; and an annual equity grant valued at $950,000. Cabat’s salary is $600,000, with a 50%-of-salary cash-bonus target and a $350,000 annual equity grant. His agreement also provided a second $125,000 bonus payable on his first employment anniversary, subject to repayment provisions for certain voluntary departures. Kuzloski and Vens had 50%-of-salary cash-bonus targets, maximums of 200% of target, and stock-bonus opportunities up to 100% of salary; their annual equity grants were $375,000 and $350,000, respectively.

FY2025–2027 LTIC target/maximum opportunities were $950,000/$1,900,000 for Consolino, $321,360/$642,720 for Kuzloski, and $267,800/$535,600 for Vens. Vens also received $357,513 for outstanding LTIC entitlements upon departure.

At year-end, NEOs held no stock options. Unvested RSUs, valued at the company’s $132.45 per-share fair market value, were:

Executive Unvested RSUs Value
Consolino 15,803 $2.093107 million
Wanamaker 4,160 $550,992
Warner 2,913 $385,827
Kuzloski 6,238 $826,223

RSUs generally vest in thirds over three years and can accelerate on specified qualifying events. The company says grant sizing considers dilution and compensation expense.

At December 31, 2025, hypothetical qualifying-termination totals for Consolino were $10.944110 million with a change in control (CIC), $6.810993 million without a CIC, and $3.847417 million for death or disability. His CIC total included $7.017240 million cash severance, $1.754310 million prorated bonus, $79,453 health benefits and $2.093107 million accelerated RSUs. Kuzloski’s corresponding totals were $2.488029 million, $2.139166 million and $1.147583 million. Wanamaker’s and Warner’s listed qualifying-termination and death/disability amounts consisted only of accelerated RSUs: $284,502 and $199,337, respectively. CEO and former General Counsel agreements provide salary-plus-target-bonus severance, prorated bonuses and health benefits, with enhanced lump-sum terms for qualifying termination within two years after a CIC; payments are subject to release and restrictive-covenant conditions and a potential Section 280G after-tax benefit limitation. Vens’s June 12, 2025 departure resulted in $1.230498 million cash severance, the $357,513 LTIC payment and $754,719 in RSUs vested after termination without cause.

The 2020 Equity Plan reserved up to 935,041 shares and otherwise runs through December 1, 2030. The company expects offering-related RSU grants to employees, including executives, but disclosed no aggregate share amount or executive allocations, leaving potential incremental dilution unquantified.

Board compensation and leadership

In FY2025, Larson received a $200,000 Vice Chairman retainer; Addesso, DeCarlo, O’Shea, Pope Davis and Watson each received $150,000 as directors; and Cooper received $100,000 as a Board advisor. Directors elected to receive cash fees in fully vested common shares. Delaney received $555,000 in consulting fees. Executive Chairman Noonan received $300,000 salary, $300,000 grant-date value of RSUs and $32,478 other compensation, for reported total compensation of $632,478; he held 4,992 RSUs at year-end. Consolino received no additional director compensation. Noonan stepped down as Executive Chairman in May 2026, when Consolino became Board Chair; Kuzloski stepped down May 27, 2026. The Compensation Committee reviews executive and director compensation using peer and broader market information, without targeting a specific peer-group pay percentile.

Principal and selling stockholders

Principal and Selling Stockholders

The section presents beneficial ownership before and after the offering, including scenarios with no exercise and full exercise of the underwriters’ option. The calculations assume the Preferred Stock Conversion has occurred and that the selling stockholders sell the shares offered.

The identified 5% holders and selling stockholders are Corinthian DF Holdings, LP; Cavello Bay Reinsurance Limited; Aquiline Financial Services Fund IV L.P.; David P. Delaney Jr.; and Timothy D. Delaney. The section also covers named executive officers and directors Joseph E. (“Jeff”) Consolino, Evan M. Cabat, William C. Vens, Robert F. Kuzloski, Jeffrey C. Wanamaker, and Cathryn Crites Warner, as well as the executive officers and directors as a group.

The supplied excerpt does not include ownership share counts or percentages, the number of shares offered by each selling stockholder, or a completed ownership measurement date. Consequently, ownership concentration and the offering’s effect on each holder’s ownership cannot be quantified from this excerpt.

Description of capital stock

Capital stock and dividends

After the offering, the company does not expect to have preferred shares issued or outstanding. Common stock carries one vote per share and no preemptive, conversion, or subscription rights. Dividends may be paid only if declared by the Board and legally payable.

The Board may establish preferred-stock series and set their dividend, redemption, liquidation, conversion, and voting terms. Subject to applicable law and NYSE rules, it may generally issue authorized preferred shares without further stockholder approval. An issuance could dilute common-stock voting power, limit common dividends, subordinate common holders in a liquidation, affect the common-stock price, or deter or delay a change of control.

Dividend decisions are discretionary and subject to legal, financial, regulatory, contractual, and other constraints. The company’s ability to pay dividends also depends on distributions from its insurance subsidiaries: SSIC, SNIC, SLAICO, LIC, LICNJ, and American Surety.

Governance and potential takeover impediments

The charter, bylaws, and Delaware law contain provisions that may preserve Board and management continuity but could delay or prevent a change of control, including a transaction that offers stockholders a premium. These include:

  • The Board’s authority to issue authorized shares and fill director vacancies;
  • Delaware General Corporation Law Section 203, which generally restricts business combinations with a stockholder owning 15% or more for three years, absent specified approvals;
  • No cumulative voting, and special stockholder meetings that may be called only by the Board or its chair;
  • Advance-notice and information requirements for director nominations and stockholder proposals, and a prohibition on stockholder action by written consent; and
  • A 75% voting threshold for stockholders to amend the bylaws, and for amendments or repeal of specified charter provisions.

The charter generally selects Delaware courts for specified internal-affairs claims and federal courts for federal securities-law claims. Enforceability may be uncertain for some claims, potentially requiring litigation in multiple jurisdictions and increasing costs. The charter also broadly renounces corporate opportunities for principal stockholders, their affiliates, and non-employee directors, subject to stated exceptions; those parties may pursue opportunities that might otherwise benefit the company, creating potential conflicts.

Director and officer protections

The charter limits directors’ monetary liability for fiduciary-duty breaches to the extent Delaware law permits, including certain claims based on gross negligence. Exculpation does not cover breaches of loyalty, bad faith, knowing or intentional violations of law, improper dividends or redemptions, or improper personal benefits; it also does not limit officer liability in derivative actions.

The bylaws generally require indemnification and advancement of expenses for directors and officers to the fullest extent permitted by Delaware law. The company expects to enter into director indemnification agreements and may maintain directors’ and officers’ insurance. These protections may discourage or reduce derivative litigation, including claims that could benefit the company and stockholders, while leaving the company potentially responsible for settlement costs or damages.

Registration rights and listing

After the offering and expiration or waiver of applicable lock-ups, certain Pre-IPO Investors and permitted transferees will have demand and piggyback registration rights, subject to customary conditions and market cutbacks. The company will provide customary registration support and indemnification for certain registration-statement misstatements or omissions, except those based on information supplied by the investors. These rights could facilitate future sales of existing shares and create potential market overhang.

The company intends to apply to list its common stock on the NYSE under the symbol CORE.

Shares eligible for future sale

Shares eligible for future sale

No public market for CORE common stock existed before the offering. The filing cautions that substantial future sales, or the perception that sales may occur, could pressure the share price and impair CORE’s ability to raise equity capital.

Shares sold in the offering will generally be freely tradable when the offering is completed. Other outstanding shares are restricted securities unless registered or eligible for an exemption. CORE, its directors and executive officers, and its stockholders—including selling stockholders—are expected to agree to a 180-day lock-up, subject to exceptions and underwriter consent.

After the lock-up period:

  • Non-affiliates: Holders who have held shares for at least six months may generally sell under Rule 144 subject to public-information requirements. After holding for one year, they may sell without Rule 144’s requirements.
  • Affiliates: Holders meeting the six-month holding period may generally begin selling 90 days after the prospectus, subject to Rule 144 limits. In any three-month period, sales are limited to the greater of 1% of shares then outstanding or the average weekly trading volume during the preceding four calendar weeks, along with applicable manner-of-sale, notice and public-information requirements.
  • Rule 701 shares: Shares issued under employee and other compensatory plans and eligible under Rule 701 may generally be resold 90 days after the offering’s effective date; different Rule 144 conditions apply to affiliates and non-affiliates.

CORE intends to register shares issuable under its amended and restated 2020 Equity Plan on Form S-8, which would make registered plan shares available for public-market sale. The company also intends to grant certain existing stockholders customary demand and piggyback registration rights. The timing and volume of any sales are uncertain and will depend on market prices and individual holders’ circumstances.

Federal income tax considerations for non u s ho

U.S. Federal Income Tax Considerations for Non-U.S. Holders

The discussion applies to non-U.S. holders of common stock acquired in the offering and held as a capital asset. It excludes the tax consequences of the Preferred Stock Conversion and does not address investors with special tax circumstances or state, local, non-U.S., estate or gift taxes, or the Medicare net-investment-income tax. The analysis reflects current law and interpretations, which may change, potentially retroactively, and is not binding on the IRS or the courts.

  • Dividends: U.S. withholding tax generally applies at 30% of gross dividends, subject to a lower rate under an applicable income tax treaty. Dividends effectively connected with a holder’s U.S. trade or business are generally taxed on a net-income basis instead. A corporate holder may also be subject to a 30% branch-profits tax, potentially reduced by treaty. Treaty benefits or effectively connected treatment generally require timely, valid IRS Form W-8 documentation.

  • Sale or other disposition: Gains generally are not subject to U.S. federal income tax unless they are effectively connected with a U.S. trade or business; an individual holder is present in the United States for at least 183 days in the disposition year and other conditions apply; or the company is a U.S. real property holding corporation (USRPHC) and applicable ownership and trading conditions are met. The company believes it is not, has not been, and does not anticipate becoming a USRPHC, but gives no assurance.

  • FATCA: A separate 30% withholding regime may apply to dividends paid to certain foreign financial institutions and non-financial foreign entities unless applicable reporting, certification, agreement or exemption requirements are satisfied. A non-financial beneficial owner may need to file a U.S. tax return to seek a refund, creating administrative burden. The entity through which the shares are held affects the analysis.

Tax consequences depend on the holder’s status, treaty eligibility and documentation, ownership and U.S. activities, and potentially changing law. Investors should obtain individualized tax advice.

Underwriting

Offering and distribution

Selling stockholders are offering the company’s common shares through J.P. Morgan Securities and Goldman Sachs as book-running managers, with BMO Capital Markets also serving as an underwriter. The underwriters are committed to purchase all offered shares if they purchase any; if an underwriter defaults, the remaining underwriters’ commitments may increase or the offering may be terminated. They also have a 30-day option to buy additional shares to cover over-allotments.

The company will apply to list its common stock on the NYSE under the ticker CORE. No public trading market existed before the offering, and the IPO price will be negotiated. There is no assurance an active market will develop or that the shares will trade at or above the IPO price. Underwriters may undertake stabilization, short-sale covering, penalty-bid and other Regulation M activities that could temporarily support or raise the market price; these activities may end at any time.

Lockups and potential conflicts

The company, its directors and executive officers, selling stockholders, and substantially all other stockholders are subject to 180-day lockups, subject to specified exceptions. J.P. Morgan and Goldman Sachs may waive or release these restrictions at their discretion. Exceptions include certain employee equity-plan activity, award exercises and settlements, conversions, permitted transfers, and qualifying transactions.

Affiliates of the underwriters have provided and may provide other financial services to the company. In particular, JPMorgan Chase Bank, an affiliate of J.P. Morgan Securities, is a lender under the company’s Credit Facility.

A directed share program will reserve a portion of the offering for certain employees, directors and other parties; shares purchased through the program will reduce the number available to the general public.

Selling restrictions

The offering is subject to jurisdiction-specific restrictions. In relevant EU states, offers are limited to applicable Prospectus Regulation exemptions, such as qualified investors, certain limited offers to non-qualified investors, or other permitted exemptions. In the UK, the prospectus is not approved for general-public distribution, and offers and investment communications are restricted to relevant persons and permitted exemptions.

The shares are unregistered in Japan and may be offered there or to Japanese residents only under an applicable exemption and in compliance with local law. In Hong Kong, offers are principally restricted to professional investors or other exempt circumstances. Singapore offers rely primarily on exemptions for institutional, accredited or other permitted investors; certain investment-holding corporations and trusts acquiring under Section 275 are subject to a six-month transfer restriction, subject to exceptions. The company classifies the shares in Singapore as prescribed capital markets products and Excluded Investment Products.

Experts

Independent Auditor

Ernst & Young LLP, an independent registered public accounting firm, audited Core Specialty Insurance Holdings, Inc.’s consolidated financial statements for the years ended December 31, 2025, 2024, and 2023. The prospectus includes those statements in reliance on EY’s audit report.

Where you can find additional information

Where You Can Find Additional Information

The prospectus is part of CORE’s Form S-1 registration statement and omits information contained in the registration statement and its exhibits and schedules. Following the offering, CORE expects to file annual, quarterly and current reports, proxy statements, and other materials under the Exchange Act. These filings will be available on the SEC’s website and CORE’s Investor Relations website.

Information on CORE’s website and other referenced sources is not part of the prospectus or registration statement. CORE does not authorize information outside the prospectus, and delivery of the prospectus does not imply that its information or CORE’s affairs have remained unchanged.

Financial statements

Financial performance

($M, except per-share data) Q3 2026 Q3 2025 9M 2026 9M 2025
Total revenue $690.1 $855.3 $2,157.5 $2,553.4
Net premiums earned 682.1 773.7 2,036.6 2,325.6
Net investment income 52.4 44.6 149.6 129.4
Net realized and unrealized investment gain (loss) (68.5) 16.5 (105.3) 39.0
Net incurred losses and loss adjustment expenses 438.4 532.6 1,311.1 1,632.6
Corporate and other expenses 11.3 1.4 — —
Net income (loss) (1.4) 51.7 84.9 135.2
Net income attributable to common stockholders — — 68.8 111.8
Diluted EPS $(0.29) $4.24 $6.76 $11.05

Q3 revenue declined 19.3% year over year; 9M revenue declined 15.5%. Earned premiums were lower in both periods, while net investment income increased. The principal earnings pressure was the swing in realized and unrealized investment results from gains to losses. Lower incurred losses partly offset these effects. Nine-month results also included a $7.7M credit for a legal-settlement provision, versus none in 9M 2025.

Balance sheet

($M) September 30, 2026 December 31, 2025
Total assets $9,780.6 $8,261.8
Total liabilities 8,170.5 6,734.3
Total stockholders’ equity 1,445.1 1,362.5
Preferred stock classified as mezzanine equity 165.0 165.0
Goodwill 89.8 89.8
Definite-lived intangible assets (excluding goodwill) 57.0 62.0
Tangible common equity* 1,298.3 —
Loss and loss adjustment expense reserves 4,721.9 4,238.8
Unearned premiums 1,994.6 1,508.0
Reinsurance balances payable 715.7 294.2
Long-term debt 397.0 372.0
Trading fixed maturities, at fair value 4,287.9 3,973.1
Premiums receivable 1,417.1 830.2
Prepaid reinsurance premiums 652.8 362.4
Property and casualty recoverables from reinsurers, net of credit allowance 2,055.7 1,806.7

*Tangible common equity is calculated as stockholders’ equity less goodwill and definite-lived intangible assets.

The balance sheet expanded alongside higher insurance reserves and reinsurance-related balances. Premiums receivable and prepaid reinsurance premiums also increased substantially, while earned premiums declined.

Cash flow and capital

($M) 9M 2026 9M 2025
Operating cash flow $440.4 $611.5
Investing cash flow (446.3) (449.5)
Capital expenditures (fixed-asset purchases) 8.6 66.6
Financing cash flow 11.9 (10.9)
Ending cash, cash equivalents, and restricted cash 287.8 393.6

Operating cash flow fell year over year. It included a $121.3M adjustment for unrealized losses on trading securities, compared with a $31.2M adjustment for unrealized gains in 9M 2025; working-capital movements also included increased cash uses from premiums receivable and prepaid reinsurance premiums. Financing included $25.0M of revolving-credit borrowings. Share repurchases were $5.8M versus $2.1M, while dividends were $4.7M in each period.

Common shares outstanding were 10,127,370 at the start of 9M 2026 and 10,120,129 at period-end; 77,082 shares were held in treasury at September 30. Share-compensation expense was $7.3M in both nine-month periods.

Financial statements

Core Specialty Insurance Holdings — financial statements

Amounts in millions unless otherwise noted.

Q3 and nine-month results

Line item Q3 2026 Q3 2025 9M 2026 9M 2025
Net premiums earned $682.1 $773.7 $2,036.6 $2,325.6
Fees and commission income 24.0 20.6 76.6 59.5
Net investment income 52.4 44.6 149.6 129.4
Net realized and unrealized investment gains (losses) (68.5) 16.5 (105.3) 39.0
Total revenue 690.1 855.3 2,157.5 2,553.4
Net incurred losses and LAE 438.4 532.6 1,311.1 1,632.6
Non-underwriting G&A expense 17.1 4.6 58.3 20.1
Interest expense 5.3 5.6 15.0 16.5
Income (loss) before taxes (1.7) 66.2 108.3 172.6
Net income (loss) (1.4) 51.7 84.9 135.2

Revenue fell 19.3% in Q3 and 15.5% in 9M. The sharp reversal in investment results was the principal drag: unrealized losses on fixed-maturity trading securities were $84.5 million in Q3 and $121.3 million in 9M 2026; gains on other investments partly offset them by $16.1 million in each period. Net investment income increased, while realized investment losses were small. Q3 had a $0.3 million tax benefit versus $14.5 million expense in Q3 2025; 9M tax expense was $23.4 million versus $37.4 million. Effective tax rates were 17.6% and 21.6%, respectively.

Segment underwriting results

Segment Q3 2026 revenue Q3 2025 revenue Q3 2026 underwriting profit (loss) Q3 2025 underwriting profit (loss)
Property & Short-tail $210.8 $293.8 $22.5 $24.1
Specialty Casualty 391.2 398.8 18.9 1.3
Bond, Credit & Guarantee 104.1 101.7 5.2 (10.7)

Segment revenue comprises net premiums earned and fee and commission income. Total underwriting profit was $46.6 million in Q3 versus $14.7 million; for 9M it was $143.2 million versus $41.5 million. Property & Short-tail revenue declined with lower premiums, but favorable incurred losses supported 9M underwriting profit. Specialty Casualty’s Q3 improvement reflected lower losses and operating expenses. Bond, Credit & Guarantee improved on lower incurred losses, partly offset in 9M by higher acquisition costs.

Premiums, reinsurance and reserves

Premium measure Q3 2026 Q3 2025 9M 2026 9M 2025
Gross premiums written $1,023.3 $996.7 $4,015.4 $3,775.2
Total ceded premiums 464.4 460.8 1,782.6 1,168.1
Net premiums written 558.9 535.9 2,232.8 2,607.1

Higher ceded premiums, especially to third parties, reduced 9M net premiums written despite growth in gross premiums. Net incurred losses and LAE decreased, while 9M ceded losses increased to $1,054.4 million from $849.1 million. Prior-year reserve development was $32.9 million favorable in 9M 2026 versus $9.0 million unfavorable in 2025: Property & Short-tail was $52.9 million favorable, Specialty Casualty $26.6 million unfavorable, and Bond, Credit & Guarantee $6.6 million favorable. Specialty Casualty adverse development reflected frequency in Excess Casualty and deterioration in a non-renewed program.

Reserve / reinsurance balance Sep. 30, 2026 Dec. 31, 2025
Gross loss and LAE reserves $4,721.9 $4,303.4
Net loss and LAE reserves 2,794.8 2,556.4
Reinsurance recoverables on unpaid claims, net of allowance 1,927.1 1,682.4
Total reinsurance recoverables, net of allowance 2,153.2 1,908.2
Prepaid reinsurance premiums 652.8 362.4
Reinsurance balances payable 715.7 294.2

About 83% of recoverables were from reinsurers rated A- or better; about 17% were subject to collateral arrangements. Agriculture premiums are substantially assumed from ceding reinsurers; two reinsurers represented about 21% of 9M gross premiums written versus 18% in 2025. Three wholesale brokers generated 39% versus 42%; Amwins’ share fell to about 30% from 40%. The Enstar/Clarendon legacy transfer has a $130.0 million adverse-development limit above $464.4 million of assumed reserves; related unpaid claims were $86.5 million at September 30. SIBL stop-loss coverage remaining across 2016–2020 underwriting years was $794.2 million.

Financial position, debt and liquidity

Balance-sheet measure Dec. 31, 2025 Dec. 31, 2024
Total assets $8,261.8 $7,326.2
Total liabilities 6,734.3 5,920.9
Total stockholders’ equity 1,362.5 1,240.3
Preferred stock classified as mezzanine equity 165.0 165.0
Goodwill 89.8 86.0
Definite-lived intangible assets 62.0 62.4

At September 30, 2026, goodwill was $89.8 million, unchanged from year-end 2025. Other intangible assets totaled $85.4 million, comprising $57.0 million of definite-life intangibles—customer relationships $16.0 million, distribution networks $37.9 million, renewal rights $1.7 million and trade names $1.4 million—and $28.4 million of indefinite-life insurance licenses. Nine-month amortization was $5.0 million versus $7.2 million.

Selected balance Sep. 30, 2026 Dec. 31, 2025
Trading fixed maturities, fair value $4,287.9 $3,973.1
Long-term debt, principal 397.3 372.3
Long-term debt, carrying value 397.0 372.0

The $361.5 million drawn under the $500 million unsecured revolver was due October 13, 2027; its rate was 5.13%. Management identified substantial doubt because repayment depends on extending, refinancing or replacing the facility, but concluded the doubt was alleviated, citing refinancing history, lender relationships, covenant compliance, liquidity and operating performance. Lender discussions began in October 2026, and management considered an extension or replacement probable. The FHLB of Atlanta offered maximum borrowing capacity of $603 million, with no active funding agreements at either reported date.

At December 31, 2025, tangible equity—stockholders’ equity less goodwill and definite-lived intangibles—was $1,210.7 million. At that date cash, cash equivalents and restricted cash totaled $281.8 million. Restricted assets were $401.0 million at September 30, 2026, including $371.9 million of restricted fixed maturities and $25.6 million of restricted cash.

Annual context, cash flow and other matters

FY measure 2025 2024 2023
Total revenue $3,370.8 $3,217.2 $2,480.0
Net income 118.9 167.0 116.3

FY2025 revenue growth did not prevent lower earnings: net income available to common stockholders was $96.5 million versus $139.0 million, and diluted EPS was $9.53 versus $13.82. Net incurred losses and LAE were $2,128.1 million versus $2,080.3 million; acquisition costs rose to $626.3 million from $567.5 million and G&A to $338.2 million from $298.4 million. Results also included a $25.0 million legal-settlement provision and a $72.0 million software-asset abandonment loss.

FY cash-flow measure 2025 2024
Operating cash flow $616.7 $715.6
Capital expenditures 17.0 71.4

FY2025 operating cash flow included a $704.4 million inflow from changes in insurance claims and reserves, partly offset by a $196.0 million outflow from changes in reinsurance recoverables. Common shares outstanding were 10.010273 million at the start of 2025 and 10.093723 million at year-end. At Q3 2026, diluted weighted-average shares were 10.120 million versus 10.117 million; 1.684 million preferred shares were excluded as antidilutive.

The auditor identified valuation of the $2.6 billion of IBNR reserves at December 31, 2025 as a critical audit matter, citing judgment and estimation uncertainty, particularly in long-duration and high-severity casualty business. The auditor’s opinion on the 2025 and 2024 financial statements was unmodified; no internal-control audit opinion was provided. Other notable items include a $13.3 million Q3 payment to former Lancer stockholders and a further $11.1 million settlement payment made in October; a California bail-bond class-action settlement for $15.2 million, subject to court approval; and preliminary net Hurricane Isaias losses of $3–$5 million expected to affect Q4.

Section

Core Specialty — FY2025 overview

Core Specialty is a U.S.-focused specialty insurer that has expanded through acquisitions and renewal-rights transactions, broadening its property and casualty, life and health, surety, and financial-services businesses. Recent additions include American National’s Specialty Markets Group and American Surety in 2024, followed in January 2025 by Argo professional-lines renewal rights and London Aviation Underwriters. At December 31, 2025, beneficial ownership (assuming preferred-share conversion) was 43% Corinthian DF Holdings, 20% Cavello Bay Reinsurance, 8% Aquiline, 14% directors and management, and 15% other investors.

Consolidated results

Amounts in millions, except where indicated.

Line item FY2025 FY2024 FY2023
Total revenue $3,370.8 $3,217.2 $2,480.0
Net premiums earned $3,072.7 $2,968.1 —
Fees and commissions $82.0 $76.5 —
Net investment income $176.5 $146.5 $98.9
Net realized and unrealized investment gains $39.5 $26.4 $39.7
Income before income taxes $148.7 $221.2 $133.0
Income tax expense $29.8 $54.2 $16.7

Revenue increased 4.8%, but pretax income declined as underwriting profit weakened and one-time charges weighed on results. Net investment income, driven largely by fixed-maturity income, rose to $176.5 million from $146.5 million. FY2025 investment gains included $37.1 million of unrealized gains, chiefly $31.8 million on trading fixed maturities. The effective tax rate was 20%, down from 25%; the 2025 provision included $2.3 million of R&D tax credits.

Segment underwriting results

Segment revenue is net premiums earned plus fees and commissions; underwriting profit is the company’s segment performance measure.

Segment Revenue FY2025 Revenue FY2024 Underwriting profit (loss) FY2025 FY2024
Property & Short-tail $1,208.1M $1,369.2M $101.6M $93.8M
Specialty Casualty $1,560.0M $1,306.9M $(4.4)M $23.0M
Bond, Credit & Guarantee $386.6M $368.5M $(17.2)M $(1.7)M

Total underwriting profit fell to $80.0 million from $115.1 million. Specialty Casualty’s growth in premiums was accompanied by higher incurred losses ($1,055.9 million versus $848.5 million) and acquisition costs ($308.1 million versus $249.8 million), driving its shift to an underwriting loss. Bond, Credit & Guarantee’s loss widened as acquisition costs rose, while Property & Short-tail improved despite lower revenue.

Underwriting reconciliation (millions) FY2025 FY2024
Net premiums earned $3,072.7 $2,968.1
Fees and commissions $82.0 $76.5
Incurred losses and LAE $(2,128.1) $(2,080.3)
Acquisition costs $(626.3) $(567.5)
Operating expenses $(320.3) $(281.7)
Underwriting profit $80.0 $115.1

Reserves, premiums, and reinsurance

Net premiums written declined 2.1% to $3.0889 billion from $3.1539 billion, while net premiums earned rose 3.5%. Net incurred losses and LAE increased to $2.1281 billion from $2.0803 billion. Gross loss and LAE reserves were $4.2388 billion at year-end, with $1.6824 billion of net reinsurance recoverables, leaving net ending reserves of $2.5564 billion, up from $2.0867 billion.

FY2025 included $41.5 million of unfavorable prior-year reserve development, versus $2.5 million in FY2024. Favorable property and bond development was outweighed by crop deterioration and casualty adverse development, including higher Excess Casualty severity, retained program losses, and Medical Stop-Loss development. Reserve estimates are sensitive to claims severity, inflation, legal trends, and long reporting and payment lags; revisions affect earnings when identified.

Net reinsurance recoverables were $1.9082 billion, up from $1.7122 billion; the related credit-loss allowance was $4.7 million. The top 10 reinsurers represented 59.1% of gross recoverables. National Indemnity was the largest exposure at $337.2 million (17.6%), followed by Enstar at $135.0 million (7.1%). The company remains liable to policyholders if reinsurers fail to perform. Its Enstar loss portfolio transfer covers specified legacy StarStone business and includes $130.0 million of adverse-development cover above $464.4 million of assumed reserves. A replacement catastrophe-bond placement provides $95 million of per-occurrence coverage through June 2028, at approximately $7.1 million annually.

Investments, debt, and other balance-sheet items

Trading fixed-maturity investments at fair value totaled $3.9731 billion, up from $3.3529 billion. Level 3 assets were $56.2 million, including $42.9 million of equity-method investments and $13.3 million of privately placed debt. Restricted assets were $369.6 million, primarily fixed maturities held for reinsurance collateral and regulatory requirements. Cash and cash equivalents were $274.8 million.

Principal debt was $372.3 million at both year-ends; carrying debt was $372.0 million in 2025. It included $336.5 million drawn on a revolving facility, $19.6 million of junior subordinated debentures, and a $10.0 million surplus note. The facility’s maturity was extended to October 2027 in February 2026; its year-end rate was 4.95%, and FY2025 interest expense was $18.7 million versus $22.1 million. The company reported compliance with its debt covenants. It also had $505 million of maximum FHLB borrowing capacity and no FHLB advances outstanding.

Intangible assets FY2025 year-end FY2024 year-end
Goodwill $89.8M $86.0M
Definite-life intangible assets $62.0M $62.4M
Indefinite-life insurance licenses $28.4M $28.4M

No goodwill or indefinite-lived intangible impairment was recorded. The company recognized a $72.0 million loss on abandoned capitalized technology projects, compared with $8.1 million in FY2024, following a strategic review and discontinuation of several systems initiatives. It also accrued $25.0 million for a probable adverse outcome in a California class action against American Surety concerning bail-bond market conduct; management said the matter could materially adversely affect financial position and results.

Capital and dilution

Diluted weighted-average shares were 10.1268 million in FY2025 versus 10.0600 million in FY2024; basic weighted-average shares were 10.0796 million and 9.9988 million. Diluted shares included 47,189 unvested-award shares. Additionally, 1.6841 million preferred shares were excluded as anti-dilutive in each of FY2023–FY2025. Preferred shares have a 1:1 mandatory conversion feature in certain change-in-control events. Each insurance subsidiary exceeded minimum risk-based capital requirements, though American Surety reported a $35.8 million statutory loss in FY2025. Subsidiaries paid $30.7 million in dividends to the company, and could pay up to $166.6 million in 2026 without prior regulatory approval.

Schedule i summary of investments

Investments as of December 31, 2025

Investments other than in related parties had a net amortized cost of $4.0183 billion, compared with fair value and balance-sheet value of $3.9771 billion—a $41.2 million fair-value shortfall. Trading fixed maturities accounted for nearly all of the portfolio; other investments were $4.0 million at both amortized cost and fair value.

Investment category Amortized cost Fair value / balance-sheet amount
Trading fixed maturities $4.0143B $3.9731B
└ Corporate $2.8685B $2.8564B
└ Collateralized loan obligations $825.3M $827.3M
└ Residential mortgage-backed securities $172.8M $146.9M
└ U.S. government $54.2M $53.3M
└ Municipal $54.2M $51.9M
└ Commercial mortgage-backed securities $23.6M $22.3M
└ Other asset-backed securities $13.7M $13.2M
└ Foreign government $2.0M $1.8M
Other investments $4.0M $4.0M
Total investments, net $4.0183B $3.9771B

Residential mortgage-backed securities produced the largest category shortfall, with fair value $25.9 million below amortized cost. CLOs were the exception among the listed fixed-maturity categories, with fair value $2.0 million above amortized cost.

Schedule ii condensed financial statements of re

Parent-company financial results

The parent company’s earnings are largely dependent on its subsidiaries: equity in subsidiary earnings accounted for almost all of parent-company revenue in FY2025.

$ millions FY2025 FY2024 FY2023
Revenue $133.5 $186.0 $129.5
Equity in earnings of subsidiaries $133.2 $184.4 $130.2
Income before tax, as reported $116.0 $159.7 $115.2
Tax expense, as reported $2.9 $7.3 $1.1
Net income, as reported $118.9 $167.0 $116.3

The reported income-statement figures do not reconcile: reported net income exceeds reported pretax income less tax expense in each of the three years. The tax line may be mislabeled, or the figures otherwise require clarification.

Parent-company balance sheet and cash flows

$ millions Dec. 31, 2025 Dec. 31, 2024
Total assets $1,871.9 $1,762.2
Investment in subsidiaries $1,850.4 $1,732.8
Cash and cash equivalents $3.4 $8.2
Total liabilities $344.4 $356.9
Long-term debt $336.5 $336.5
Mezzanine equity $165.0 $165.0
Stockholders’ equity $1,362.5 $1,240.3
$ millions FY2025 FY2024 FY2023
Operating cash flow $(12.1) $3.7 $(7.7)
Financing cash flow $16.0 — —
Cash interest paid $18.6 $22.3 $10.5
Interest expense $18.7 $22.1 $10.6

FY2025 operating cash flow was negative despite reported net income, principally because the reconciliation deducted $133.2 million of equity earnings from subsidiaries. Financing cash flow was positive $16.0 million, including $30.8 million of subsidiary dividends, partly offset by $6.3 million of parent cash dividends, $2.1 million of share repurchases, $1.2 million of contributions to subsidiaries, and $5.2 million of contingent consideration payments. Subsidiary dividends were $25.0 million in FY2024 and $14.5 million in FY2023.

The parent’s low standalone cash balance and reliance on subsidiary earnings and distributions are important liquidity considerations.

Schedule iii supplementary insurance information

FY2025 supplementary insurance information

Dollars in millions. Balance-sheet amounts are at year-end.

Net premiums earned grew 3.5% in FY2025, while net premiums written declined 2.1%. The shift reflects strong earned-premium growth in Specialty Casualty offset by lower premiums in Property & Short-tail and lower writings in Bond, Credit & Guarantee. FY2023 net premiums earned were $2,296.6 and net premiums written were $2,523.1.

Consolidated insurance item FY2025 FY2024
Net premiums earned $3,072.7 $2,968.1
Net premiums written $3,088.9 $3,153.9
Incurred losses and loss-adjustment expenses $2,128.1 $2,080.3
Acquisition costs $626.3 $567.5
Operating expenses $320.3 $281.7
Loss reserves, year-end $4,238.8 $3,522.3
Unearned premiums, year-end $1,508.0 $1,439.4

Written premiums remained slightly above earned premiums in FY2025, but the difference narrowed from FY2024. Loss reserves rose 20.3%, substantially faster than earned premiums, while acquisition costs and operating expenses also increased.

Segment premiums and underwriting costs

Segment item FY2025 FY2024
Property & Short-tail
Net premiums earned $1,173.5 $1,347.1
Net premiums written $1,110.5 $1,250.4
Incurred losses $863.9 $1,010.9
Acquisition costs $160.5 $195.4
Operating expenses $82.1 $69.1
Loss reserves, year-end $674.0 $722.4
Specialty Casualty
Net premiums earned $1,514.7 $1,253.7
Net premiums written $1,585.4 $1,369.1
Incurred losses $1,055.9 $848.5
Acquisition costs $308.1 $249.8
Operating expenses $200.4 $185.6
Loss reserves, year-end $3,458.5 $2,722.5
Bond, Credit & Guarantee
Net premiums earned $384.5 $367.3
Net premiums written $393.0 $534.4
Incurred losses $208.3 $220.9
Acquisition costs $157.7 $122.3
Operating expenses $37.8 $27.0

Property & Short-tail earned premiums fell 12.9%; its FY2023 earned premiums were $1,280.5. Specialty Casualty earned premiums rose 20.8%, continuing growth from $1,015.8 in FY2023. Its loss reserves increased 27.0% and accounted for the largest segment contribution to the increase in total reserves. Bond, Credit & Guarantee earned premiums grew 4.7%, but written premiums fell 26.4%; its FY2023 earned and written premiums were both only $0.3, a minimal comparison base.

Approximate underwriting contribution

The following is net premiums earned less incurred losses, acquisition costs, and operating expenses. It excludes investment income and is not the company’s reported segment profit.

Segment FY2025 FY2024
Property & Short-tail $67.0 $71.7
Specialty Casualty $(49.7) $(30.2)
Bond, Credit & Guarantee $(19.3) $(2.9)
Total $(2.0) $38.6

Net investment income is not allocated to segments, so these amounts do not represent full segment profitability. Overall, premium growth shifted toward Specialty Casualty, while contracting Property & Short-tail premiums and lower Bond, Credit & Guarantee writings limited total written-premium growth.

Schedule iv reinsurance

Schedule IV — Reinsurance

Amounts in $ millions. Net reinsurance amounts were nearly flat year over year in Property & Casualty but declined in Accident & Health.

Business line Measure 2025 2024 2023
Accident & Health Gross $415.9 $294.1 $3.2
Ceded $(437.0) $(420.7) $(30.5)
Assumed $42.7 $156.0 $28.9
Net $21.6 $29.4 $1.6
Property & Casualty Gross $2,672.5 $2,476.9 $2,243.7
Ceded $(1,040.6) $(913.1) $(923.6)
Assumed $1,435.4 $1,560.7 $1,201.4
Net $3,067.3 $3,124.5 $2,521.5
  • Accident & Health: Net reinsurance fell 26.5% in 2025 from 2024 despite higher gross amounts. Ceded amounts exceeded gross amounts in both years. Assumed amounts were 197.7% of net in 2025, down from 530.6% in 2024 and 1,806.3% in 2023.
  • Property & Casualty: Net reinsurance declined 1.8% in 2025 after increasing 23.9% from 2023 to 2024. Assumed amounts were 46.8% of net in 2025, compared with 50.0% in 2024 and 47.6% in 2023.

Schedule v valuation of qualifying accounts

Schedule V — Valuation of Qualifying Accounts

Dollars in millions; allowance balances shown as deductions.

Allowance Jan. 1, 2023 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2025
Deferred-tax-asset valuation allowance $(0.2) — — $(0.2)
Uncollectible reinsurance recoverables $(6.7) $(7.7) $(7.7) $(4.7)
Uncollectible premiums receivable $(3.0) — $(3.6) $(3.7)

The deferred-tax-asset valuation allowance was unchanged from Jan. 1, 2023, through Dec. 31, 2025. For reinsurance recoverables, the allowance increased by $1.0 in 2023, with that amount charged to costs and expenses; no charge was recorded in 2024. In 2025, the allowance declined by $3.0, with a $3.0 credit/allowance reduction charged to costs and expenses. For premiums receivable, charges to costs and expenses were $(0.5) in 2023, $(0.1) in 2024, and $(0.1) in 2025. No amounts were written off in any of the periods shown.

Schedule vi supplementary information concerning

Core Specialty — Schedule VI supplementary information

Dollars in millions; fiscal years ended 2025, 2024 and 2023.

Earned premiums and investment income grew in FY2025, while written premiums declined. Incurred-loss ratios improved for a third consecutive year, although prior-year loss development and paid losses were higher than in FY2024. Acquisition costs also rose faster than earned premiums.

Selected operating results

Line item FY2025 FY2024 FY2023
Net premiums earned $3,072.7 $2,968.1 $2,296.6
Net premiums written $3,088.9 $3,153.9 $2,523.1
Net incurred losses and loss adjustment expenses $2,128.1 $2,080.3 $1,684.9
└ Current-year incurred losses and expenses $2,086.6 $2,077.8 $1,643.4
└ Prior-year incurred losses and expenses $41.5 $2.5 $41.5
Acquisition costs, including amortization of value of business acquired $626.3 $567.5 $410.7
Net paid losses and loss adjustment expenses $1,658.4 $1,506.8 $1,332.7
Net investment income $176.5 $146.5 $98.9

Net premiums earned increased 3.5% in FY2025, following substantial growth in FY2024. Net premiums written fell 2.1% in FY2025 after increasing in FY2024. The incurred-loss ratio, calculated using net premiums earned, improved to approximately 69.3% from 70.1% in FY2024 and 73.4% in FY2023. However, prior-year incurred losses rose to $41.5 million from $2.5 million in FY2024. Acquisition costs increased 10.4%, and net paid losses increased 10.1% year over year. Net investment income rose 20.5%.

Selected operating balances

Line item FY2025 FY2024 FY2023
Deferred acquisition costs and value of business acquired $239.5 $226.3 $175.3
Reserves for losses and loss adjustment expenses $4,238.8 $3,522.3 $2,710.1
Unearned premiums $1,508.0 $1,439.4 $1,239.9

Loss reserves increased to $4,238.8 million in FY2025 from $3,522.3 million in FY2024.

Feedback